D-Finitive Technologies

D-Finitive Technologies is a biopharmaceutical company specializing in the discovery and development of next-generation therapeutics using Targeted Protein Degradation (TPD). Based in Hyderabad, India, the company utilizes its proprietary D-PROTAC platform to design bifunctional small molecules that selectively degrade disease-causing proteins by hijacking the cellular ubiquitin-proteasome system. Their current research pipeline primarily targets high-value oncology indications, focusing on well-validated but difficult-to-treat proteins such as the Androgen Receptor and Estrogen Receptor. By completely removing target proteins rather than just inhibiting them, D-Finitive aims to overcome drug resistance and provide more durable clinical outcomes for patients with cancer and immunological disorders.